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Regulation of protein trafficking between the nucleus and cytoplasm represents a novel control point for
antineoplastic intervention. Several proteins involved with cellular growth and survival depend on precise and
timely positioning within the cell to fulfill their functions, and the nuclear membrane defines one of the most
important compartmental barriers. Chromosome Region Maintenance 1, or exportin-1 (CRM1/XPO1), is involved with
the export of more than 200 nuclear proteins, and has intriguingly been shown to have an increased expression in
several tumor cell types. Selinexor (KPT-330) is a first-in-class selective inhibitor of nuclear export (SINE) to be developed
for clinical use. Preclinical data has demonstrated antineoplastic activity of SINE compounds in many human solid and
hematologic malignancies. The clinical development of Selinexor provides an excellent model for translational research.SINE – translational science in a new class of
anti-cancer agents
There are many ways in which neoplastic cells can gain
a selective survival advantage over their non-cancerous
counterparts. While traditional chemotherapeutics target
the end result of cell division caused by many trans-
formative events, more recent ‘targeted therapies’ have
aimed to selectively block specific aspects of neoplastic
cells that allow them to compete for resources and grow
without restraint. For the most part, targeted therapies
include those that 1) block external signals that can lead
to cell growth, 2) interrupt intracellular signal transduc-
tion or enzymatic pathways that mediate growth and/or
metabolism within neoplastic cells, or 3) thwart the can-
cer cell’s ability to evade signals and intracellular process
such as apoptosis that would otherwise lead to self de-
struction. Many of these therapeutic strategies target can-
cer cells through antibody recognition or small molecule
interaction with specific proteins that mediate pro-survival
processes. Other strategies (such as inhibition of the prote-
asome, histone deacetylases, DNA methylation and heat
shock proteins) seek to more globally manipulate theCorrespondence: gerecitj@mskcc.org
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lective advantage of tumor cells.
Regulation of protein trafficking between the nucleus
and cytoplasm represents a novel control point for anti-
neoplastic intervention. Several proteins involved with
cellular growth and survival depend on precise and
timely positioning within the cell to fulfill their func-
tions, and the nuclear membrane defines one of the most
important compartmental barriers. Although molecules
smaller than 40 kDa can passively move between the nu-
cleus and cytoplasm, larger molecules depend on active
transport mediated by karyopherin chaperones [1]. Once
such karyopherin that is exclusively engaged in nuclear ex-
port is Chromosome Region Maintenance 1, or exportin-1
(CRM1/XPO1). CRM-1 is involved with the export of
more than 200 nuclear proteins, and has intriguingly been
shown to have an increased expression in several tumor
cell types [2-9]. The selective advantage this confers may
relate to the proteins exported by CRM1, many of which
(e.g. p53, p21, p27, pRb, FOXO, IkB) behave as tumor sup-
pressors when localized to the nucleus, thus relieving in-
hibition of cellular growth and survival when they are
exported to the cytoplasm [1].
Selinexor (KPT-330) is a first-in-class selective inhibitor
of nuclear export (SINE) to be developed for clinical use.
By interacting directly with CRM1, this drug prevents itsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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proteins that would otherwise have been destined for ex-
port to the cytoplasm. Preclinical data has demonstrated
antineoplastic activity of SINE compounds in many hu-
man solid and hematologic malignancies including renal
cell carcinoma [10], mantle cell lymphoma (MCL) [8],
chronic lymphocytic leukemia (CLL) [11], multiple mye-
loma (MM) [9], melanoma [12], acute myeloid leukemia
(AML) [13] and non-Hodgkin lymphoma (NHL) [14]. Re-
cent work has also shown that SINE compounds increase
CRM1’s proteasomal degradation, increase nuclear reten-
tion of p53 and Foxo, and lead to increased apoptosis in
prostate cancer cell lines [15].
In this issue of Journal of Hematology & Oncology,
Gravina et al. explore mechanisms by which SINE com-
pounds can affect the growth and spread of prostate cancer
tumor lines [16]. The authors use tumor lines with differ-
ent metastatic potentials and tropisms, and test tumor
biology within different in vivo models. In one model, the
authors orthotopically transplanted PCa cells into the pros-
tate glands of SCID mice. Direct growth of the orthotopic
tumor and extension into the peritoneum were both inhib-
ited by KPT-330 given at two different dose levels and dos-
ing schedules. In two models of bone metastasis, the
authors injected PCa cells into the heart or directly into
the tibiae of SCID mice. Both models showed decreased
growth of osteolytic lesions upon treatment with SINE, as
well as a decrease in markers of bone resorption and in-
creased survival of the treated mice. To further demon-
strate the antimetastatic potential of these inhibitors, the
authors demonstrated decreased migratory potential across
Boyden chambers, decreased metalloprotease production
and decreased survival of cells detached from their micro-
environment when treated with Selinexor. Perhaps even
more intriguingly, they found that Selinexor can inhibit
markers of angiogenesis and osteoclast differentiation in-
duced by contact with media conditioned by PCa cells. In
sum, these results suggest a multitude of ways that SINE
can affect the biology and natural history of prostate can-
cer, from direct inhibition of cell growth to alterations in
the microenvironment that mitigate not only metastasis,
but destructive lesions fostered by nearby tumor growth.
The clinical development of Selinexor provides an ex-
cellent model for translational research. In 2012, first-in-
man phase 1 trials of KPT-330 were begun in both solid
(NCT01607905) and hematologic (NCT01607892) ma-
lignancies (www.clinicaltrials.gov), and early reports of
these trials are showing activity in various tumor types.
At the 2013 annual meeting of the American Society of
Hematology (ASH), updated results from the hematologic
malignancy phase 1 trial demonstrated activity in patients
with multiple myeloma, Waldenstrom’s macroglobuline-
mia, AML, CLL and various subtypes of NHL [14,17,18].
Paired pre-and post-treatment biopsies obtained duringthese trials have shown increased intranuclear retention of
tumor suppressor proteins in several patients: e.g. in-
creased nuclear localization of p53 in a patient with MCL,
retention of p53, FOXO3 and IkB in MM and of FOXO1,
pRB, survivin and IkB in AML cells. Data from the solid
malignancy trial was presented at the annual meeting of
the American Society for Clinical Oncology (ASCO) in
2014, and showed decreases in disease burden in patients
with colorectal, head & neck, ovarian, cervical, prostate
and other malignancies including partial remissions in 3
tumor types [19]. Once again, paired biopsies in this trial
were able to identify increased localization of tumor sup-
pressor proteins (TSPs) including p53, p27, IkB, BRCA2
and FOX03 in various tumor types. Major side effects
across these trials have included nausea, vomiting, diar-
rhea, thrombocytopenia and weight loss (the last of which
caused the early clinical termination of a prior nuclear ex-
port inhibitor, Leptomycin B [20]), and the optimal dosing
schedule has not yet been determined.
It will be very interesting to follow prostate patients
on the phase 1 and subsequent trials that allow their in-
clusion. The model presented in this issue of JHO might
predict numerous potential benefits for such patients. If
the effects in humans reflect the in vivo experience pre-
sented here, we might expect to see direct decreases in
osseous metastasis as well as decreases in lytic lesions
caused by disruption of osteoclastogenesis in the micro-
environment. This could alleviate one of the most vexing
adverse effects of PCa – the pain that comes from bony
lesions – even if tumor burden is not measurably de-
creased. Of course, the results reported also portend
hope of improving the total disease burden, but it is too
early to tell how deep or durable these responses can be
with single-agent therapy. While these are compelling
results for a new class of agents, we anxiously await
results that will guide the optimal dosing schedule, miti-
gation of SINE-induced adverse effects, and best com-
bination treatments to pursue.
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